Published 3 days ago • loading... • Updated 3 days ago

Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy

On March 14, 2026, Vimgreen announced China's CDE approved an IND for VG081821, enabling Phase II NASH trials.
With NASH rising alongside obesity and metabolic syndrome, VG081821 as an A2A receptor antagonist targets steatosis, inflammation, and fibrosis, addressing critical unmet needs beyond resmetirom and semaglutide.
VG081821's pharmacology shows it is the only A2A receptor inverse agonist in global development, more potent than caffeine, with Phase II Parkinson's disease trials meeting efficacy expectations.
Observed safety data show transient liver transaminases elevation likely linked to hepatic de-lipidation, a pattern seen with fibrates and resmetirom, and the IND adds a second indication to Vimgreen's lead drug candidate alongside its Parkinson's program.
The company cautions that Vimgreen's press release includes forward-looking language with risks, while epidemiological studies on coffee and caffeine support A2A receptor antagonists for liver disease.

Insights by Ground AI

27 Articles

keenesentinel.com

+26 Reposted by 26 other sources

Center

Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy

HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year